The Signal
Ben, a scientist and DeSci builder, explains Pump Science's attempt to turn drug-development IP into tradeable onchain assets. The pitch is that speculation can fund experiments in areas conventional funding leaves behind—starting with longevity—while real-time animal and eventually human data gives the market something more concrete than a meme to follow.
Key Takeaways
- 01
A single-drug market
Pump Science frames a token as a fractional claim around the intellectual property of one compound, rather than a biotech stock holding many programs. Its founders say that makes an individual drug tradeable without the legal and administrative burden of negotiating an IP license.
- 02
Data is the catalyst
The first experiments track longevity compounds in flies, including movement and distance as possible leading indicators before a lifespan result. The team says it wants the generated data to be usable by both human traders and AI agents.
- 03
Speculation funds the lab
The proposed loop is trading fees funding contracted labs, then experiments progressing from worms and flies to mice and humans before a consumer product. Early launch volume is constrained by how many experiments partner labs can actually run.
- 04
Longevity's funding gap
Ben argues that aging is hard to fund because the FDA does not treat it as a disease, while insurers, VCs, public markets, and the NIH have weaker incentives to pay for broadly life-extending interventions.
- 05
Transparency over roadmaps
Asked how users can judge whether a DeSci project is legitimate, he points to auditable onchain spending and live experiments. He says prospective holders should check whether money is actually going to research rather than rely on plans alone.
On the Record
“We're basically tokenizing the intellectual property for a specific compound, and that's so you can trade. So instead of having to go buy a biotech stock where you have to hold all of the different drugs that they hold, now you can hold one.”
“Our goal is to turn degens into scientists and also scientists into degens. What's so cool about this is it's real world; it's more than just a meme.”
“The trading fees fund the research. We take that money and we send it to the labs to go run the experiments, and then eventually you've basically tested on worms, flies, mice, humans, and then we just go launch a product.”
“I would say just audit the onchain transactions. How is the money being spent? Is the money actually going towards science?”
The Breakdown
A market for one compound at a time
Ben opens by saying he is trained as a scientist but also trades crypto, and that science lacks the continuous, watchable information stream of sports betting. Pump Science is intended to make that game for science. Rather than buying a biotech company and its whole pipeline, users trade a token tied to the IP around a specific compound. He distinguishes this from a memecoin by saying the underlying asset is a real-world invention, data set, or patentable combination.
Rifampicin, urolithin A, and a data trail
The conversation turns to the two launched coins, described as rifampicin and urolithin A. Ben says the premise is to develop a compound into a future supplement and build evidence that people might want it. Initial animal work asks whether treated animals live longer; he also mentions future human measurements such as heart-rate metrics and VO2 max through a wearable-data partnership. The project plans to release compound identities ahead of launches so people can research them.
Why launches cannot be fully permissionless yet
Pump Science planned one or two tokens a day over roughly ten days, but Ben says physical laboratories, machines, and animal studies are the bottleneck. The long-term aspiration is a Pump.fun-like submission layer, while the short-term approach is a limited set of experiments. Submitted ideas arrive through a form; selected contributors become what he calls drug devs and hold the IP. Controlled substances such as ketamine and cocaine are excluded because partner labs lack the relevant licenses.
Trading activity as research funding
Ben describes the desired mechanism: a token reaches a market-cap threshold, trading has generated enough fees, and an experiment can begin. Fees go to contracted labs, with studies moving through worms, flies, mice, and ultimately people before a product launch. Supplements would be sold direct to consumers, backed by the resulting data. When Threadguy asks about product revenue, Ben says a buyback-and-burn would need a governance decision by token holders rather than being promised outright.
The case for starting with longevity
He says longevity is an easy first category because everyone ages and the outcome is intuitive, but it is poorly served by existing incentives. In his account, aging is not recognized by the FDA as a disease, so drug approval and reimbursement systems favor diagnosed illnesses such as cancer, heart disease, or diabetes. That leaves longevity research without obvious NIH, venture, public-market, or insurance funding. His answer is that individuals—and, provocatively, crypto traders—have to fund it themselves.
BioDAO's broader research menu
Ben places Pump Science in a BioDAO ecosystem that includes longevity, hair loss, women's health, and cryonics groups. He says Binance invested in BIO, an index token across those DAOs, while each group studies a different research area. Hair loss becomes the concrete example: he notes the limited existing options and says people with both crypto holdings and hair-loss concerns can coordinate around funding alternatives. He also mentions possible discussions around a DAO.fun vehicle, without presenting it as finalized.
What would make DeSci credible
Scientists' reception is mixed, Ben says: researchers starved for grants welcome funding, while others bring crypto's stigma to the project. His proposed test is openness—follow the transactions, see whether experiments are streamed, and demand evidence of delivery rather than a roadmap. He presents that transparency as the bridge between speculation and serious research. In his closing pitch, the project is for people who want more options to extend their lives, not just another digital market to trade.
Distilled from the episode transcript · Counterparty Recap Desk
